Measuring activated kinases involved in cancer signaling pathways
Official title: Immunoassay for Measuring Mutation Activated Kinases Across Multiple Cell Signaling Pathways
Funded at Adeptrix Corporation · NIH-10921330 · Data updated 2026-11-12
This study is working on a new test to help find better combinations of cancer treatments by looking at important proteins involved in cancer growth, so that patients can have more effective options for their care.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Adeptrix Corporation NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 1, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $295,230 |
| NIH project number | 1R43CA291535-01 |
| Project ID | NIH-10921330 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that involve mutations in key signaling pathways, particularly those related to AKT and BRAF.
✕Less likely to help
Patients with cancers not involving the targeted signaling pathways or those who are not candidates for drug combination therapies may not benefit from this research.
What this research studies
This research focuses on developing a new immunoassay to measure activated kinases that play a crucial role in multiple cancer signaling pathways. By analyzing specific phosphorylation of kinases and their substrates, the study aims to identify promising drug combinations for cancer treatment. The approach seeks to overcome limitations of existing methods that are either too narrow in scope or impractical for routine use. Patients may benefit from more effective treatment options based on the findings of this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by identifying the best drug combinations tailored to individual patients' tumor profiles.
How similar studies have gone: While similar approaches have been explored, this specific immunoassay for measuring multiple protein targets across various cancer pathways is novel and has not been extensively tested.
Where this research is happening
-
Adeptrix Corporation
Boston, United States Active
Researchers
- Principal investigator: Bergo, Vladislav — Adeptrix Corporation
- Study coordinator: Bergo, Vladislav
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.